Dostarlimab, a drug taken by the patients in the study, allows molecules from laboratories to act as replacement antibodies. The drug, from pharmaceutical company GlaxoSmithKline, was given every three months to study patients. At the end of the study and numerous analyzes, no trace of a tumor was detected in the bodies of the twelve patients.
Dr. Luis Diaz, study member, published in the New England Journal of Medicineassured that it was “the first time this has happened in the history of cancer”. No additional treatment was used in the patients and the patients suffered no side effects.
–
